ASTER-GUARDIANS
15.5.2023 15:28:35 CEST | Business Wire | Press release
Margaret Helen Shepherd from UK has been announced as the winner of the Aster Guardians Global Nursing Award 2023 in a prestigious award ceremony held at Queen Elizabeth II Centre in London. The winner was announced by Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare and the award was presented by Professor Jamie Waterall, Deputy Chief Public Health Nurse for the Office of Health Improvement & Disparities at Govt. of UK alongside Ms. Sheila Sobrany – President of Royal College of Nursing; Ms. Alisha Moopen, Deputy Managing Director, Aster DM Healthcare; and Mr. TJ Wilson – Executive Director and Group Head – Governance & Corporate Affairs, Aster DM Healthcare.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230515005491/en/
Margaret Helen Shepherd from the UK - Winner of the Aster Guardians Global Nursing Award 2023 (Photo: AETOSWire)
Launched on International Nurses Day in May 2021 by Aster DM Healthcare, with an aim to recognise the selfless contribution of nurses to millions of patients worldwide, Aster Guardians Global Nursing Award 2023 received an overwhelming response from nurses worldwide with over 52,000 nurses from 202 countries, a 116% growth from the last edition which had received 24,000 applications.
The award ceremony also saw a special video message from Dr. Tedros Adhanom Ghebreyesus – Director General of World Health Organisation being played to congratulate all the finalists and thank Aster DM Healthcare for the initiative.
On winning the award, Nurse Margaret said, “I am deeply humbled and grateful to receive the prestigious Aster Guardians Global Nursing Award. As healthcare professionals, we are privileged to be able to make a positive impact on the lives of our patients, and I feel blessed to be part of such a rewarding profession. This award not only recognises my personal achievements but also highlights the importance of nursing as a critical component of healthcare. Thank you to all my colleagues, mentors, and patients who have supported me throughout my career.”
Margaret has been dedicated to improving diabetes care through better diagnosis. She is the leading nurse for monogenic diabetes in the UK and provides advice to clinicians across the world regarding the management of this condition. She set up a national network of genetic diabetes nurses in 2002 to increase awareness of this condition (which is initially misdiagnosed in 80% of cases, resulting in patients being treated with unnecessary insulin injections). She was one of 70 national NIHR70@70 Senior Nurse Research Leaders (driving innovation and new roles to increase research awareness and engagement within clinical care) and has received the prestigious Florence Nightingale Foundation Leadership Scholarship.
Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare said, “We are honoured to announce Ms Margaret Helen Shepherd from the United Kingdom as the winner of this year's Aster Guardians Global Nursing Award. She has exemplified the highest standards of patient care and dedication that is inspirational, and it deserves global recognition. Each one of the top 10 finalists have done phenomenal work and the Grand Jury had a tough time assessing and selecting the final winner. We are privileged to offer Aster Guardians Global Nursing Award as a platform to share and honor the accomplishments of exceptional nurses from around the globe.”
Ms. Alisha Moopen, Deputy Managing Director, Aster DM Healthcare said, “Aster Guardians Global Nursing Award is a small yet significant expression of gratitude that aligns with this year's International Nurses Day theme, ‘Our Nurses. Our Future’. Nurses ensure that patients receive high-quality care and often go beyond their call of duty to ensure that the right care is provided. This often helps them develop into other areas like research, innovation, mentorship, education, digitization among others as the stories of this year’s finalists and the winner have showcased. We as individuals and organizations must ensure that they receive the recognition they deserve, and this is where initiatives like Aster Guardians Global Nursing Award come into play. As a group, we will continue to support and celebrate the tireless efforts of nurses and put forth their inspiring stories of excellence.”
The rest of the 9 finalists, Cathy Cribben-Pearse from UAE, Christine Mawia Sammy from Kenya, Gloria Ceballo from Panama, Jincy Jerry from Ireland, Lilian Yew Siew Mee from Singapore, Michael Joseph Dino from Philippines, Shanti Teresa Lakra from India, Teresa Fraga from Portugal, and Wilson Fungameza Gwessa from Tanzania were also awarded with a monetary prize.
These nurses were selected through a stringent review process run by Ernst & Young LLP, a panel of Screening-Jury and the Grand Jury.
About Aster DM Healthcare
Aster DM Healthcare Limited is one of the largest private healthcare service providers operating in GCC and in India. With an inherent emphasis on clinical excellence, we are one of the few entities in the world with a strong presence across primary, secondary, tertiary, and quaternary healthcare through our 30 hospitals, 125 clinics, 496* pharmacies, 20 labs and 157 patient experience centers in seven countries, including India. We reach out to all economic segments in the GCC states through our differentiated healthcare services across the “Aster”, “Medcare” and “Access” brands.
* Including 239 Pharmacies in India operated by Alfaone Retail Pharmacies Private Limited under brand license from Aster.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005491/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom